Authors:
Lederman, RJ
Tenaglia, AN
Anderson, RD
Hermiller, JB
Rocha-Singh, K
Mendelsohn, FO
Hiatt, WR
Moon, T
Whitehouse, MJ
Annex, BH
Citation: Rj. Lederman et al., Design of The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) trial, AM J CARD, 88(2), 2001, pp. 192
Authors:
Henry, TD
Rocha-Singh, K
Isner, JM
Kereiakes, DJ
Giordano, FJ
Simons, M
Losordo, DW
Hendel, RC
Bonow, RO
Eppler, SM
Zioncheck, TF
Holmgren, EB
McCluskey, ER
Citation: Td. Henry et al., Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease, AM HEART J, 142(5), 2001, pp. 872-880
Authors:
Hendel, RC
Henry, TD
Rocha-Singh, K
Isner, JM
Kereiakes, DJ
Giordano, FJ
Simons, M
Bonow, RO
Citation: Rc. Hendel et al., Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion - Evidence for a dose-dependent effect, CIRCULATION, 101(2), 2000, pp. 118-121
Authors:
Lucore, CL
Mishkel, GJ
Ligon, RW
Rocha-Singh, K
Citation: Cl. Lucore et al., Economic implications of coronary stenting with adjunctive IIb/IIIa receptor antagonists in a community hospital, J INVAS CAR, 11, 1999, pp. 14C-20C